Navigation Links
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Date:11/14/2007

Following the Screening and the Testing of Hundreds of MicroRNAs, Eight MicroRNAs Were Identified that Effectively Reduce Liver Cancer Cell Growth

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, November 14 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today the initiation of in vivo studies in its microRNA-based liver cancer therapeutic program conducted in collaboration with Isis Pharmaceuticals(1) (NASDAQ: ISIS). The project, combining Isis's extensive know how and IP in antisense chemistry and Rosetta Genomics' know how and proprietary microRNA platform technologies, is the companies' leading attempt at harnessing microRNAs' role as master switches of the human body to develop a treatment for cancer.

Out of hundreds of potential microRNAs screened and tested, eight have been identified to lead to a decrease in liver cancer cell growth when inhibited. These microRNAs will be further tested during the in vivo studies.

Liver cancer is the third most common cause of cancer deaths in men and the tenth most common in women, according to the National Cancer Institute. Approximately 20,000 people will die this year of liver cancer in the US alone.

"Rosetta and Isis decided two years ago to focus on developing a microRNA-based drug for this deadly cancer," noted Amir Avniel, CEO and President of Rosetta Genomics. "We are proud to present these results, demonstrating that microRNAs play a key role in liver cancer, and that targeting them in vitro leads to a decrease in cancer cell growth. We look forward to starting the in vivo studies."

Data on this program was presented by the two companies at the American Association for Cancer Research (AACR) conference; "The Role of Non-Coding RNAs in Cancer", held in Cambridge, Massachusetts, on Nov. 2. Slides of the presentation are available for viewing on Rosetta's web site under the Events Calendar link on the homepage.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, and the expected progress and timing of the liver cancer therapeutic program constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

(1) The liver cancer program at Rosetta Genomics is being funded in part by the Binational Industrial Research and Development Foundation (BIRD).

Contact:

Media

Alan Zachary

T: +1-312-944-6784

media@rosettagenomics.com

Investors

Juliane Snowden

T: +1-212-213-0006

investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
11. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):